Cargando…
Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
Autores principales: | Wang, Hongquan, Wu, Shuang, Wang, Yan, Tang, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Compuscript
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334757/ https://www.ncbi.nlm.nih.gov/pubmed/35856565 http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0299 |
Ejemplares similares
-
Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma
por: Liu, Jing, et al.
Publicado: (2019) -
Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression
por: Jin, Fanjie, et al.
Publicado: (2020) -
Latexin exhibits tumor-suppressor potential in pancreatic ductal adenocarcinoma
por: XUE, ZHANXIONG, et al.
Publicado: (2016) -
Surgical Treatment of Pancreatic Ductal Adenocarcinoma
por: Satoi, Sohei
Publicado: (2021) -
STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma
por: Evers, Lisa, et al.
Publicado: (2014)